Subscribe to RSS
DOI: 10.1055/s-2007-984439
© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York
Impact of Thyroid Metabolism on the Course of INR Levels in a Patient with Systemic Anticoagulation Suffering from Amiodarone-Induced Thyrotoxicosis
Publication History
received 19.09.2007
first decision 04.05.2007
accepted 14.06.2007
Publication Date:
18 October 2007 (online)
Abstract
We report the case of a 60 year old female patient on continuous systemic anticoagulation therapy with coumarin due to mechanical aortic valve replacement and a more than 3 years lasting amiodarone therapy due to severe ventricular extrasystoles suffering from amiodarone induced thyrotoxicosis (AIT). During the course of AIT, showing different thyroid metabolic conditions, INR levels revealed a course closely related to the thyroid conditions indicating a significant and clear-cut effect of both hyper- and hypothyroidism on systemic anticoagulation therapy with coumarin. This continuous interaction of different thyroid metabolic conditions and the anticoagulation state could be well documented in the presented case over a time period of approximately five months.
Key words
systemic anticoagulation - thyroid metabolism - amiodarone-induced thyrotoxicosis - INR
References
- 1 Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119 8S-21S
- 2 Chute JP, Ryan CP, Sladek G, Shakir KM. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. Endocr Pract. 1997; 3 77-79
- 3 Self TH, Straughn AB, Weisburst MR. Effect of hyperthyroidism on hypoprothrombinemic response to warfarin. Am J Hosp Pharm. 1976; 33 387-389
- 4 Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine. 2004; 83 107-113
- 5 Dykin D. Warfarin therapy. N Engl J Med. 1970; 283 801-803
- 6 Bucerius J, Joe AY, Palmedo H, Reinhardt MJ, Biersack HJ. Impact of hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. Thyroid. 2006; 16 369-374
- 7 Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med. 1986; 58 43-51
- 8 Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. West J Med. 1999; 170 49-51
- 9 Rice AJ, MacIntosh TJ, Fouts JR, Brunk SF, Wilson WR. Decreased sensitivity to warfarin in patients with myxedema. Am J Med Sci. 1971; 262 211-215
- 10 Sanoski CA, Baumann JL. Clinical observation with the amiodarone / warfarin interaction. Chest. 2002; 121 19-23
- 11 Demirkan K, Stephens MA, Newman KP, Self TH. Response to warfarin and other oral anticoagulants. Effect of disease states. South Med J. 2000; 93 448-455
- 12 Kerin NZ, Blevins RD, Goldman LK, Rubenfire M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med. 1988; 148 1779-1781
- 13 Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73 67-74
- 14 Loelinger EA, Esch B van der, Mattern MJ, Hemker HC. The biological disappearance rate of prothrombin, factors VII, IX, and X from plasma in hypothyroidism, hyperthyroidism and during fever. Thrombosis Diath Haemorrh. 1964; 10 267-277
- 15 Wintraub M, Breckenridge RT, Griner PF. The effects of dextrothyroxine on the kinetics of prothrombin activity: Proposed mechanism of the potentiation of warfarin by D-thyroxine. J Lab Clin Med. 1973; 81 273-279
Correspondence
J. BuceriusMD
Department of Nuclear Medicine
University of Bonn
Sigmund-Freud-Str. 25
53105 Bonn
Germany
Phone: +49/228/287 151 81
Fax: +49/228/287 190 96
Email: jan.bucerius@ukb.uni-bonn.de